South-East Asia Rheumatoid Arthritis Therapeutics Market 2022 South-East Asia Rheumatoid Arthritis Therapeutics

South-East Asia Rheumatoid Arthritis
Therapeutics Market is expected to
increase in value at a CAGR of 4.7%
2022: Radiant Insights, Inc
“Over the 2015-2022 forecast period, the South-East
Asia RA therapeutics market is expected to increase
in value at a CAGR of 4.7%, from $1.04 billion to
over $1.4 billion.”
Summary
Rheumatoid Arthritis (RA) is a chronic, progressive and currently incurable autoimmune disease
that primarily affects the joints. It is characterized by synovial inflammation and gradual bone
erosion over many years. Disease progression results in stiffness and pain, especially in the hands
and feet, which hinders mobility. Without treatment, the disease leads to joint destruction and
disability.
The chronic nature of the disease, which requires ongoing treatment, and the relatively high
annual cost of therapy (ACoT) have made RA treatment a highly lucrative market.
The RA therapeutic market has become very competitive due to the high number of new drug
approvals. Competition is fierce, particularly among TNF-α inhibitors,
Access Full Report With TOC @ http://www.radiantinsights.com/research/rheumatoid-
arthritis-therapeutics-in-south-east-asia-markets-to-2022
Follow Us: